10 Innovative Healthcare Stocks to Watch in 2025

4. Johnson & Johnson (NYSE:JNJ)

Number of Hedge Fund Holders: 98

Johnson & Johnson (NYSE:JNJ) develops, manufactures, and sells a range of products in the healthcare field through its subsidiaries. The business is divided into two segments: Innovative Medicine and MedTech, with a primary focus on goods about human health and well-being. Infectious diseases, immunology, neuroscience, metabolic and cardiovascular disorders, pulmonary hypertension, and oncology are among the therapeutic specialties covered by its Innovative Medicine division. A wide variety of medical devices and products utilized in the domains of cardiovascular intervention, orthopedics, interventional solutions, surgery, and vision are included in the MedTech section.

The foundation of Johnson & Johnson (NYSE:JNJ) is solid. For fiscal year 2024, it recorded sales of $88.8 billion, a 4.3% increase over the previous year. The company’s high-growth strategy is reflected in these impressive outcomes. Its cash flow from operations is sufficient to pay its high-yielding dividend, and its financial sheet is sound.

The corporation announced on January 13 that it will acquire neurological medication manufacturer IntraCellular for $14.6 billion. Through this acquisition, the business will have access to Caplyta, an oral medication used to treat schizophrenia and bipolar disorder.

Asad Haider, an analyst at Goldman Sachs, returned to coverage of Johnson & Johnson (NYSE:JNJ) on April 9 with a Buy rating and a $172.00 price target. Morgan Stanley maintained its Equal Weight rating on the company’s shares while increasing its price objective from $163 to $164.